Phospholipids for Pediatric Dosage Forms
PharmaExcipients.com
PharmaExcipients.com is an unique information and exchange platform on major topics related to pharmaceutical excipients
Are you familiar with phospholipids for pediatric dosage forms? We got great insights during this years EUPfI Conference in Rotterdam thanks to the excellent presentation The role of phospholipids in infant nutrition and their use as safe and effective excipients for pediatric formulations by Richard Wibel from Lipoid GmbH, Germany. But there is more to share and we gladly share the latest update from September 30, 2024 by Lipoid on this topic.
Phospholipids for Pediatric Dosage Forms
Safe and Endogenous Compounds for Pharmaceutical Applications
Phospholipids are ubiquitous, endogenous, and nutritional compounds. For pharmaceutical applications, phospholipids are safe and versatile excipients for any administration route. This is demonstrated by their long-standing use in several innovative pediatric drug products and their recognition by regulatory authorities. The excellent tolerability and safety profile of phospholipids is underscored by their presence in breast milk and infant formula, making them one of the first nutrients that infants ingest.
Excipient Selection for Pediatric Drug Products
Formulating drug products for children poses unique challenges. nbsp;Excipients are key components in the formulation of age-appropriate drug products that are suitable for the envisaged administration route, API, and target age group. In addition to functionality and quality, taste and palatability of the dosage form are typical aspects of drug formulation for children. Moreover, particular attention has to be paid to excipient safety.As endogenous compounds with an established regulatory framework, phospholipids perfectly fulfill existing safety and quality requirements. Moreover, they provide versatile functionalities and are compatible with a wide range of age-appropriate dosage forms (Figure 1).
领英推荐
Concluding Remarks
Regulatory authorities require consideration of pediatric dosage forms early during the product development. The unique needs of children in terms of safety and efficacy must therefore be considered when selecting excipients. Because of their excellent safety profile, multifunctionality, and compatibility with a wide variety of dosage forms, phospholipids are ideally suited for this purpose. Moreover, they allow simultaneous development of pediatric and adult formulations, as well as conversion of adult formulations to pediatric ones without the need to exchange excipients. Various organizations have confirmed the safety of lecithin and phospholipids from a regulatory perspective including their suitability for pediatric formulations.Lipoid provides phospholipids in cGMP quality from small to large scale to support your product development from pre-clinical to clinical and commercial stages.
Philippe Tschopp Andreas Sch?fer Balder Rebmann